Beam Therapeutics Email Format

Beam Therapeutics uses the firstinitiallast format on beamtx.com, so Jane Smith would be jsmith@beamtx.com.

Risto-cel is Beam Therapeutics' lead investigational therapy targeting severe sickle cell disease. It works by activating fetal hemoglobin through ex vivo base editing and is currently in a Phase 1/2 clinical trial called BEACON.

Beam Therapeutics was founded in 2017 by gene editing pioneers David R. Liu, Feng Zhang, J. Keith Joung, Nicole Gaudelli, and Alexis Komor, with John Evans joining as CEO that same year to lead the company.

Beam Therapeutics' base editing platform makes precise single-letter changes to DNA without causing double-stranded breaks, which reduces the risk of unpredictable insertions, deletions, or larger genomic rearrangements associated with traditional CRISPR approaches.

Beam Therapeutics has a notable collaboration with Pfizer focused on in vivo base editing programs for targets in the liver, muscle, and central nervous system, which began with a $300 million upfront payment from Pfizer in 2022. Tools like Clay can help identify the right Beam Therapeutics contact for partnership or business development inquiries.